Gilead Sciences Inc.
333 Lakeside Drive
Foster City,
CA 94404
United States - Map
Phone: 650-574-3000
Fax: 650-578-9264
Web Site: http://www.gilead.com
| Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases. Its products include Truvada, Viread, Atripla, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, amphotericin B liposome injection to treat serious invasive fungal infections; Flolan, an injected medication for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension; and Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS). The company also offers Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms; and Cicletanine, which is being evaluated for the treatment of pulmonary arterial hypertension. Gilead Sciences has operations in North America, Europe, and Australia. The company has research collaborations with Abbott Laboratories, Inc.; Novartis Institutes for BioMedical Research, Inc.; Novartis Vaccines and Diagnostics, Inc.; Genelabs Technologies, Inc.; Achillion Pharmaceuticals, Inc.; Japan Tobacco, Inc.; Parion Sciences, Inc.; LG Life Sciences, Ltd.; and University of Texas System. It also has commercial collaborations with Astellas Pharma, Inc.; Emory University; F. Hoffmann-La Roche, Ltd.; Pfizer, Inc.; Dainippon Sumitomo Pharma Co., Ltd.; OSI Pharmaceuticals, Inc.; GlaxoSmithKline, Inc.; Japan Tobacco, Inc.; and Bristol-Myers Squibb Company. The company was founded in 1987 and is headquartered in Foster City, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. John C. Martin Ph.d., 57
Chairman and Chief Exec. Officer |
$
2.66M |
$
32.89M | Dr. John F. Milligan PhD, 48
Pres and Chief Operating Officer |
$
1.17M |
$
7.88M | Dr. Norbert W. Bischofberger Ph.D., 53
Chief Scientific Officer and Exec. VP of R&D |
$
1.16M |
$
23.01M | Mr. Gregg H. Alton , 43
Sr. VP, Sec. and Gen. Counsel |
$
651.00K |
$
4.77M | Mr. Kevin Young , 51
Exec. VP of Commercial Operations |
$
972.00K |
$
2.54M |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.31% Nasdaq 
1.12%
Profile
